|View printer-friendly version|
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
“During the third quarter, we took important steps to advance our lead programs for Parkinson’s disease and Huntington’s disease with the presentation of positive long-term clinical results and the filing of an IND, respectively. Together with our partner, Neurocrine, we are currently focused on resuming enrollment in the RESTORE-1 clinical trial for Parkinson’s disease pending the requested review and assessment of patient imaging data by the
Recent Program and Corporate Highlights
VY-AADC (NBIb-1817) for Parkinson’s Disease
- Voyager and Neurocrine Biosciences (Neurocrine) are developing VY-AADC (NBIb-1817) as a one-time AAV-based gene therapy encoding the gene for human AADC that is designed to help produce the AADC enzyme in brain cells where it can convert levodopa to dopamine. VY-AADC (NBIb-1817) is administered into the brain using magnetic resonance imaging (MRI)-facilitated targeted delivery.
September 2020, Voyager and Neurocrine presented new positive long-term, three-year data from the PD-1101 Phase 1b trial, and two-year data from the PD-1102 trial, demonstrating that a one-time treatment with VY-AADC (NBIb-1817) showed sustained improvement in motor function including greater mean ON time without troublesome dyskinesia, reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores, and reduction in the amount of Parkinson’s disease medications in these patients. The data were presented at the MDS Virtual Congress2020.
November 2020, the Data Safety Monitoring Board (DSMB) for the RESTORE-1 Phase 2 clinical trial reviewed certain patient imaging data from the ongoing trial and recommended a pause in the dosing of patients in RESTORE-1 pending review by the DSMBof additional data. As previously announced, trial sites participating in RESTORE-1 are not currently screening and enrolling patients as a result of the COVID-19 pandemic. In response to the DSMB’s recommendation, Voyager and Neurocrine have decided to delay the planned resumption of patient screening in the RESTORE-1 trial until the DSMBis able to complete its evaluation. The DSMBis expected to consider additional patient data before year-end. Neurocrine is preparing an expedited safety report that will be submitted to the FDA within the 15-day reporting window.
VY-HTT01 for Huntington’s Disease
- Voyager is developing VY-HTT01 as a one-time AAV-based gene therapy treatment designed to knock down expression of the HTT gene. Voyager’s approach is focused on delivering VY-HTT01 directly into the brain and targeting a reduction of the levels of HTT protein in the striatum and cortex to potentially slow the progression of both motor and cognitive symptoms.
September 2020, Voyager submitted an IND application for VY-HTT01 in Huntington’s disease, and in October, Voyager was notified that the IND had been placed on clinical hold pending the resolution of certain CMC information requests. Voyager recently received written feedback from the FDA requesting additional information on specific CMC topics, including drug-device compatibility and drug substance and product characterization. Voyager plans to work closely with the agency to resolve the additional information request in a timely manner.
- Following clearance of the IND by the FDA, Voyager expects to begin a Phase 1b clinical trial of VY-HTT01 in Huntington’s disease patients.
Novel AAV Capsid Discovery Program
- Voyager continues to progress its efforts in the discovery and engineering of novel AAV capsids with the potential to overcome the limitations of existing capsids, including greater blood-brain barrier (BBB) penetrance following IV administration. Voyager is leveraging its proprietary TRACER™ platform to facilitate the selection of AAV capsids with significantly improved BBB crossing and cell-specific transduction properties.
- Voyager is currently engaged in advanced non-human primate studies to further characterize and select novel AAV capsids with improved properties offering the potential for therapeutic applications in neurological disorders.
Recent Corporate Updates
- Voyager recently made key appointments of leaders across several functional areas. These include the appointments of
Michelle Quinn Smithas Chief Human Resources Officer, Diana M. Collazo, Ph.D., J.D. as Chief Patent Counsel and Claire Sampson, Ph.D. as Vice President, Global Regulatory Affairs.
- Voyager recently appointed
Nancy Vitaleas an independent director to its Board of Directors, effective as of September 15, 2020. Ms. Vitalebrings more than 25 years of business and human resources experience to Voyager’s Board. She is a former Senior Vice President and Chief Human Resource Officer at Genentech, a member of the Roche Group.
Third Quarter 2020 Financial Results
- Collaboration Revenues: Voyager recorded collaboration revenue of
$117.8 millionfor the third quarter of 2020, compared to collaboration revenue of $20.4 millionfor the same period of 2019. The increase in collaboration revenue was a result of the termination of the AbbVie collaborations in August 2020and the subsequent recognition of all remaining deferred amounts under the agreements.
- Net Income: Net income was
$85.6 millionfor the third quarter of 2020, compared to a net loss of $15.0 millionfor the same period of 2019.
- R&D Expenses: Research and development expenses were
$25.0 millionfor the third quarter of 2020, compared to $29.8 millionfor the same period in 2019. The decrease in R&D expenses was primarily related to lower external costs for services supporting Voyager’s clinical and preclinical pipeline programs.
- G&A Expenses: General and administrative expenses were
$8.3 millionfor the third quarter of 2020, compared to $8.5 millionfor the same period in 2019. The decrease in G&A expenses was primarily attributable to a decrease in professional fees supporting Voyager’s pipeline programs.
- Cash Position: Cash, cash equivalents and marketable debt securities as of
September 30, 2020were $200 million.
- Based on the Company’s current operating plan, Voyager anticipates cash, cash equivalents and marketable debt securities will be between
$150 millionand $170 millionat the end of 2020.
- Voyager expects that its cash, cash equivalents and marketable debt securities, as well as amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, will be sufficient to meet Voyager’s projected operating expenses and capital expenditure requirements into mid-2022.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding Voyager’s ability to deliver patient imaging data to the
All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the ability to provide imaging data to the
VP, Investor Relations
Selected Financial Information
($-amounts in thousands, except per share data)
|Three Months Ended||Nine Months Ended|
|Statement of Operations Items:||2020||2019||2020||2019|
|Research and development||25,039||29,777||86,757||83,184|
|General and administrative||8,277||8,463||26,721||26,444|
|Total operating expenses||33,316||38,240||113,478||109,628|
|Operating income (loss)||84,527||(17,807||)||51,113||(37,911||)|
|Total other income||1,084||2,801||1,554||6,888|
|Net income (loss)||$||85,611||$||(15,006||)||$||52,667||$||(31,023||)|
|Net income (loss) per share, basic||$||2.30||$||(0.41||)||$||1.42||$||(0.87||)|
|Net income (loss) per share, diluted||$||2.27||$||(0.41||)||$||1.40||$||(0.87||)|
|Weighted-average common shares outstanding, basic||37,242,504||36,742,993||37,079,242||35,581,408|
|Weighted-average common shares outstanding, diluted||37,672,328||36,742,993||37,500,155||35,581,408|
|Selected Balance Sheet Items||2020||2019|
|Cash, cash equivalents, and marketable debt securities||$||200,018||$||281,533|
|Accounts payable and accrued expenses||$||25,051||$||25,586|
|Total stockholders’ equity||$||166,236||$||99,512|
Source: Voyager Therapeutics, Inc.